We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Burning Rock Biotech Ltd | NASDAQ:BNR | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.38 | 5.57 | 7.07 | 6.79 | 6.79 | 6.79 | 514 | 01:00:00 |
Recent Business Updates
First Quarter 2022 Financial Results
Revenues were RMB135.5 million (US$21.4 million) for the three months ended March 31, 2022, representing a 27.1% increase from RMB106.6 million for the same period in 2021.
Cost of revenues was RMB47.9 million (US$7.6 million) for the three months ended March 31, 2022, representing a 61.5% increase from RMB29.7 million for the same period in 2021, primarily due to the Company’s continued business growth, increased depreciation in relation to our new laboratory and inventory write downs.
Gross profit was RMB87.6 million (US$13.8 million) for the three months ended March 31, 2022, representing a 13.8% increase from RMB76.9 million for the same period in 2021. Gross margin was 64.6% for the three months ended March 31, 2022, which decreased from 72.2% for the same period in 2021 primarily due to the increased depreciation in relation to our new laboratory and inventory write downs.
Non-GAAP gross profit, which excludes depreciation and amortization, was RMB92.7 million (US$14.6 million) for the three months ended March 31, 2022, representing a 20.2% increase from RMB77.1 million for the same period in 2021. Non-GAAP gross margin was 68.4% for the three months ended March 31, 2022, compared to 72.4% for the same period in 2021 primarily due to an increase of RMB4.8 million in inventory write downs (which resulted in a 3.5 percentage-point decrease of gross margin).
Operating expenses were RMB350.4 million (US$55.3 million) for the three months ended March 31, 2022, representing a 40.9% increase from RMB248.8 million for the same period in 2021. The increase was primarily driven by headcount growth to support our business expansion.
Net loss was RMB261.4 million (US$41.2 million) for the three months ended March 31, 2022, compared to RMB171.4 million for the same period in 2021.
Cash, cash equivalents, restricted cash and short-term investments were RMB1,502.9 million and RMB1,338.4 million (US$211.1 million) as of December 31, 2021 and March 31, 2022, respectively.
2022 Financial Guidance
Given the strong first quarter business performance and assuming that the impact of COVID-19 dissipates over time in China, Burning Rock reiterates its full year 2022 revenue guidance of approximately RMB620 million (US$97.8 million), implying a 22% growth over full year 2021.
Conference Call Information
Burning Rock will host a conference call to discuss the first quarter 2022 financial results at 8:30 a.m. U.S. Eastern Time (8:30 p.m. Hong Kong time) on May 31, 2022.
Details of the conference call are as follows:
International: | +65 67135640 |
U.S.: | +1 3322089718 |
U.K.: | +44 2036928124 |
Hong Kong: | +852 30186768 |
China Mobile: | 4008209615 |
China Landline: | 8008207535 |
Conference ID: | 8942518 |
A replay of the conference call will be available for one week (dial-in number: +61 2 8199 0299; same conference ID as shown above).
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
For more information about Burning Rock, please visit: ir.brbiotech.com.
Safe Harbor Statement
This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
Non-GAAP Measures
In evaluating the business, the company considers and uses non-GAAP measures, such as non-GAAP gross profit and non-GAAP gross margin, as supplemental measures to review and assess operating performance. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The company defines non-GAAP gross profit as gross profit excluding depreciation and amortization. The company defines non-GAAP gross margin as gross margin excluding depreciation and amortization.
The company presents these non-GAAP financial measures because they are used by management to evaluate operating performance and formulate business plans. The company believe non-GAAP gross profit and non-GAAP gross margin excluding non-cash impact of depreciation and amortization reflect the company’s ongoing business operations in a manner that allows more meaningful period-to-period comparisons.
Contact: IR@brbiotech.com
Selected Operating Data | |||||||||
For the three months ended | |||||||||
March 31,2021 | June 30,2021 | September 30,2021 | December 31,2021 | March 31,2022 | |||||
Central Laboratory Channel: | |||||||||
Number of patients tested | 7,716 | 8,1551,013300 | 7,808 | 8,235 | 7,743 | ||||
Number of ordering physicians(1) | 1,082 | 1,013 | 920 | 917 | 994 | ||||
Number of ordering hospitals(2) | 303 | 300 | 287 | 306 | 318 |
(1) Represents physicians who on average order at least one test from us every month during a relevant period in the central laboratory channel.(2) Represents hospitals whose residing physicians who on average order at least one test from us every month during a relevant period in the central laboratory channel.
As of | |||||||||
March 31,2021 | June 30,2021 | September 30,2021 | December 31,2021 | March 31,2022 | |||||
In-hospital Channel: | |||||||||
Pipeline partner hospitals(1) | 22 | 22 | 24 | 23 | 24 | ||||
Contracted partner hospitals(2) | 32 | 34 | 34 | 41 | 41 | ||||
Total number of partnerhospitals | 54 | 56 | 58 | 64 | 65 |
(1) Refers to hospitals that are in the process of establishing in-hospital laboratories, laboratory equipment procurement or installation, staff training or pilot testing using the Company’s products. (2) Refers to hospitals that have entered into contracts to purchase the Company’s products for use on a recurring basis in their respective in-hospital laboratories the Company helped them establish. Kit revenue is generated from contracted hospitals.
Selected Financial Data | |||||||||
For the three months ended | |||||||||
Revenues | March 31,2021 | June 30,2021 | September 30,2021 | December 31,2021 | March 31,2022 | ||||
(RMB in thousands) | |||||||||
Central laboratory channel | 74,561 | 79,999 | 78,817 | 85,976 | 74,211 | ||||
In-hospital channel | 28,994 | 40,502 | 43,714 | 51,906 | 48,957 | ||||
Pharma research and development channel | 3,068 | 6,778 | 4,084 | 9,463 | 12,356 | ||||
Total revenues | 106,623 | 127,279 | 126,615 | 147,345 | 135,524 |
For the three months ended | |||||||||
Gross profit | March 31,2021 | June 30,2021 | September 30,2021 | December 31,2021 | March 31,2022 | ||||
(RMB in thousands) | |||||||||
Central laboratory channel | 55,212 | 58,681 | 58,387 | 65,985 | 50,574 | ||||
In-hospital channel | 20,070 | 29,426 | 31,111 | 34,194 | 33,396 | ||||
Pharma research and development channel | 1,658 | 2,124 | 2,098 | 5,200 | 3,610 | ||||
Total gross profit | 76,940 | 90,231 | 91,596 | 105,379 | 87,580 |
For the three months ended | |||||||||||
Share-based compensation expenses | March 31,2021 | June 30,2021 | September 30,2021 | December 31,2021 | March 31,2022 | ||||||
(RMB in thousands) | |||||||||||
Cost of revenues | 339 | 406 | 267 | 492 | 365 | ||||||
Research and development expenses | 22,404 | 20,825 | (9,559 | ) | (4,033 | ) | 12,299 | ||||
Selling and marketing expenses | 2,633 | 2,809 | 2,044 | 2,126 | 1,774 | ||||||
General and administrative expenses | 59,382 | 59,369 | 60,803 | 62,126 | 65,715 | ||||||
Total share-based compensation expenses | 84,758 | 83,409 | 53,555 | 60,711 | 80,153 |
Burning Rock Biotech Limited Unaudited Condensed Statements of Comprehensive Loss (in thousands, except for number of shares and per share data) | ||||||||||||||||||
For the three months ended | ||||||||||||||||||
March 31,2021 | June 30,2021 | September 30,2021 | December 31,2021 | March 31,2022 | March 31,2022 | |||||||||||||
RMB | RMB | RMB | RMB | RMB | US$ | |||||||||||||
Revenues | 106,623 | 127,279 | 126,615 | 147,345 | 135,524 | 21,379 | ||||||||||||
Cost of revenues | (29,683 | ) | (37,048 | ) | (35,019 | ) | (41,966 | ) | (47,944 | ) | (7,563 | ) | ||||||
Gross profit | 76,940 | 90,231 | 91,596 | 105,379 | 87,580 | 13,816 | ||||||||||||
Operating expenses: | ||||||||||||||||||
Research and development expenses | (77,414 | ) | (108,071 | ) | (69,649 | ) | (112,724 | ) | (119,496 | ) | (18,850 | ) | ||||||
Selling and marketing expenses | (55,130 | ) | (68,058 | ) | (76,687 | ) | (103,221 | ) | (89,211 | ) | (14,073 | ) | ||||||
General and administrative expenses | (116,259 | ) | (116,130 | ) | (116,304 | ) | (141,563 | ) | (141,733 | ) | (22,358 | ) | ||||||
Total operating expenses | (248,803 | ) | (292,259 | ) | (262,640 | ) | (357,508 | ) | (350,440 | ) | (55,281 | ) | ||||||
Loss from operations | (171,863 | ) | (202,028 | ) | (171,044 | ) | (252,129 | ) | (262,860 | ) | (41,465 | ) | ||||||
Interest income | 787 | 681 | 958 | 1,031 | 1,832 | 289 | ||||||||||||
Interest expenses | (510 | ) | (565 | ) | (367 | ) | (94 | ) | 119 | 19 | ||||||||
Other income (expense), net | 118 | 433 | 20 | (372 | ) | 298 | 47 | |||||||||||
Foreign exchange gain (loss), net | 57 | (560 | ) | 380 | (731 | ) | (777 | ) | (123 | ) | ||||||||
Loss before income tax | (171,411 | ) | (202,039 | ) | (170,053 | ) | (252,295 | ) | (261,388 | ) | (41,233 | ) | ||||||
Income tax (benefits) expenses | - | (1,626 | ) | (424 | ) | 1,151 | - | - | ||||||||||
Net loss | (171,411 | ) | (203,665 | ) | (170,477 | ) | (251,144 | ) | (261,388 | ) | (41,233 | ) | ||||||
Net loss attributable to Burning Rock Biotech Limited’s shareholders | (171,411 | ) | (203,665 | ) | (170,477 | ) | (251,144 | ) | (261,388 | ) | (41,233 | ) | ||||||
Net loss attributable to ordinary shareholders | (171,411 | ) | (203,665 | ) | (170,477 | ) | (251,144 | ) | (261,388 | ) | (41,233 | ) | ||||||
Loss per share for class A and class B ordinary shares: | ||||||||||||||||||
Class A ordinary shares - basic and diluted | (1.65 | ) | (1.96 | ) | (1.64 | ) | (2.40 | ) | (2.50 | ) | (0.39 | ) | ||||||
Class B ordinary shares - basic and diluted | (1.65 | ) | (1.96 | ) | (1.64 | ) | (2.40 | ) | (2.50 | ) | (0.39 | ) | ||||||
Weighted average shares outstanding used in loss per share computation: | ||||||||||||||||||
Class A ordinary shares - basic and diluted | 86,721,263 | 86,764,260 | 86,908,975 | 87,128,297 | 87,179,752 | 87,179,752 | ||||||||||||
Class B ordinary shares - basic and diluted | 17,324,848 | 17,324,848 | 17,324,848 | 17,324,848 | 17,324,848 | 17,324,848 | ||||||||||||
Other comprehensive income (loss), net of tax of nil: | ||||||||||||||||||
Foreign currency translation adjustments | 14,080 | (34,980 | ) | 6,146 | (24,726 | ) | (3,065 | ) | (483 | ) | ||||||||
Total comprehensive loss | (157,331 | ) | (238,645 | ) | (164,331 | ) | (275,870 | ) | (264,453 | ) | (41,716 | ) | ||||||
Total comprehensive loss attributable to Burning Rock Biotech Limited’s shareholders | (157,331 | ) | (238,645 | ) | (164,331 | ) | (275,870 | ) | (264,453 | ) | (41,716 | ) |
Burning Rock Biotech LimitedUnaudited Condensed Consolidated Balance Sheets(In thousands) | |||||
As of | |||||
December 31,2021 | March 31,2022 | March 31,2022 | |||
RMB | RMB | US$ | |||
ASSETS | |||||
Current assets: | |||||
Cash and cash equivalents | 1,431,317 | 1,265,792 | 199,674 | ||
Restricted cash | 7,795 | 9,083 | 1,433 | ||
Short-term investments | 63,757 | 63,482 | 10,014 | ||
Accounts receivable, net | 92,197 | 103,616 | 16,345 | ||
Contract assets, net | 42,391 | 43,923 | 6,928 | ||
Inventories, net | 123,210 | 130,175 | 20,535 | ||
Prepayments and other current assets, net | 60,279 | 69,331 | 10,937 | ||
Total current assets | 1,820,946 | 1,685,402 | 265,866 | ||
Non-current assets: | |||||
Equity method investment | 910 | 773 | 122 | ||
Property and equipment, net | 325,438 | 322,171 | 50,821 | ||
Operating right-of-use assets | 81,007 | 72,501 | 11,437 | ||
Intangible assets, net | 5,150 | 4,246 | 669 | ||
Other non-current assets | 45,136 | 22,703 | 3,581 | ||
Total non-current assets | 457,641 | 422,394 | 66,630 | ||
TOTAL ASSETS | 2,278,587 | 2,107,796 | 332,496 |
Burning Rock Biotech LimitedUnaudited Condensed Consolidated Balance Sheets (Continued)(in thousands) | ||||||||
As of | ||||||||
December 31,2021 | March 31,2022 | March 31,2022 | ||||||
RMB | RMB | US$ | ||||||
LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | 63,080 | 97,892 | 15,442 | |||||
Deferred revenue | 142,871 | 159,148 | 25,105 | |||||
Accrued liabilities and other current liabilities | 127,892 | 104,092 | 16,420 | |||||
Customer deposits | 972 | 972 | 153 | |||||
Short-term borrowing | 2,370 | 2,370 | 374 | |||||
Current portion of operating lease liabilities | 34,999 | 35,298 | 5,568 | |||||
Total current liabilities | 372,184 | 399,772 | 63,062 | |||||
Non-current liabilities: | ||||||||
Non-current portion of operating lease liabilities | 49,316 | 39,811 | 6,280 | |||||
Other non-current liabilities | 11,776 | 13,636 | 2,151 | |||||
Total non-current liabilities | 61,092 | 53,447 | 8,431 | |||||
TOTAL LIABILITIES | 433,276 | 453,219 | 71,493 | |||||
Shareholders’ equity: | ||||||||
Class A ordinary shares | 116 | 116 | 19 | |||||
Class B ordinary shares | 21 | 21 | 3 | |||||
Treasury stock | - | (3,258 | ) | (514 | ) | |||
Additional paid-in capital | 4,280,956 | 4,357,933 | 687,447 | |||||
Accumulated deficits | (2,228,713 | ) | (2,490,101 | ) | (392,804 | ) | ||
Accumulated other comprehensive loss | (207,069 | ) | (210,134 | ) | (33,148 | ) | ||
Total shareholders’ equity | 1,845,311 | 1,654,577 | 261,003 | |||||
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | 2,278,587 | 2,107,796 | 332,496 |
Burning Rock Biotech LimitedUnaudited Condensed Statements of Cash Flows(in thousands) | ||||||||
For the three months ended | ||||||||
March 31,2021 | March 31,2022 | March 31,2022 | ||||||
RMB | RMB | US$ | ||||||
Net cash used in operating activities | (113,145 | ) | (144,361 | ) | (22,772 | ) | ||
Net cash generated from (used in) investing activities | 288,329 | (13,011 | ) | (2,050 | ) | |||
Net cash used in financing activities | (4,162 | ) | (3,934 | ) | (621 | ) | ||
Effect of exchange rate on cash, cash equivalents and restricted cash | 16,658 | (2,931 | ) | (464 | ) | |||
Net increase (decrease) in cash, cash equivalents and restricted cash | 187,680 | (164,237 | ) | (25,907 | ) | |||
Cash, cash equivalents and restricted cash at the beginning of period | 1,925,206 | 1,439,112 | 227,014 | |||||
Cash, cash equivalents and restricted cash at the end of period | 2,112,886 | 1,274,875 | 201,107 | |||||
Burning Rock Biotech LimitedReconciliations of GAAP and Non-GAAP Results | ||||||||||||||
For the three months ended | ||||||||||||||
March 31,2021 | June 30,2021 | September 30,2021 | December 31,2021 | March 31,2022 | ||||||||||
(RMB in thousands) | ||||||||||||||
Gross profit | 76,940 | 90,231 | 91,596 | 105,379 | 87,580 | |||||||||
Add: depreciation and amortization | 206 | 437 | 1,382 | 1,981 | 5,139 | |||||||||
Non-GAAP gross profit | 77,146 | 90,668 | 92,978 | 107,360 | 92,719 | |||||||||
Total revenues | 106,623 | 127,279 | 126,615 | 147,345 | 135,524 | |||||||||
Gross margin | 72.2 | % | 70.9 | % | 72.3 | % | 71.5 | % | 64.6 | % | ||||
Non-GAAP gross margin | 72.4 | % | 71.2 | % | 73.4 | % | 72.9 | % | 68.4 | % |
1 Year Burning Rock Biotech Chart |
1 Month Burning Rock Biotech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions